Kornimate/medical-research-clean huggingface dataset:
egg effects on atherogenic dyslipidemias, glucose metabolism and inflammation in diabetic subjects

Conditions: Diabetes Mellitus; Inflammation

Summary: there is concern in the literature regarding egg consumption in diabetic people. the investigators hypothesis is that compared to an oatmeal-based breakfast, an egg-based breakfast will not increase the risk for heart disease in diabetic people but it may reduce inflammation, in this population characterized by chronic low grade inflammation. this is a cross-over study in which subjects will be randomly allocated to consume 1 egg per day for breakfast or a bowl of oatmeal with lactose-free milk for 5 weeks. after a 3 wk washout period, subjects will be allocated to the alternate treatment for additional 5 weeks. blood will be collected at baseline and at the end of each dietary period to measure plasma lipids, glucose, insulin, glycosylated hemoglobin and inflammatory markers.

this study is conducted in diabetic patients who are given two distinct breakfasts: eggs and oatmeal in a crossover design. the investigators hypothesis is that eggs will not increase the risk for heart disease in this population when compared to oatmeal but they will more likely reduce inflammation due to the presence of the carotenoids, lutein and zeaxanthin that are highly available in eggs. in this study, the investigators are evaluating three main things * atherogenic dyslipidemia by measuring plasma lipids and lipoprotein mean size and subfractions by nuclear magnetic resonance. * glucose metabolism by measuring plasma glucose, insulin, insulin resistance and glycosylated hemoglobin. * inflammation by measuring liver enzymes, c reactive protein, tumor necrosis factor-alpha, interleukin-6. all these measurements were done 24 weeks after completion of the study all data will be presented 1 year after completion of the study

Eligibility criteria:
inclusion criteria: * diabetic subjects diagnosed by physician * male and female * 35-65 years * glycosylated hemoglobin \< 9% exclusion criteria: * taking ezetimibe * heart disease * renal problems * cancer * thyroid problems

Keywords: egg oatmeal atherogenic dyslipidemia glycosylated hemoglobin inflammatory markers
postoperative outcomes within an enhanced recovery after surgery protocol (power2)

Conditions: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee

Summary: methods national audit of a 60-day prospective observational cohort in the that the pre-defined postoperative complications at 30 days of follow-up in adult patients electively undergoing hip replacement surgery (hrs) or knee replacement surgery (krs) with or without a program of enhanced recovery (eras: enhanced recovery after surgery) with any level of protocol compliance (0-100%) research places spanish hospitals where these surgical interventions are performed usually objectives to determine the incidence of postoperative complications per patient and procedure, regardless of the degree of adherence to eras protocols and its impact on the hospital stay and on postoperative complications including 30-day mortality sample size for an alpha error of 5% (95% confidence and an accuracy of 3% and estimating a number of patients with complications of 50%, the calculation of sample size yields 3012 patients, although the final sample size may be smaller depending on the proportion of complications detected. inclusion criteria patients over 18 undergoing elective hrs or krs ptc regardless of its affiliation to a eras program and the level of compliance with protocol (from 0-100%) statistical analysis continuous variables will be described as mean and standard deviation, if it is a normal distribution, or median and interquartile range, if they are not distributed normally. the comparisons of continuous variables are performed by one-way anova or the mann-whitney test, depending on proceed a univariate analysis will be carried out to test the factors associated with postoperative complications, hospital stay and death in hospital. univariate analyzes and logistic regression models will be constructed hierarchical multivariate to identify the factors associated in a independent with these results and to adjust the differences in the factors of confusion. the factors will be introduced in the models based on their relationship with the univariate result (p \<0.05), the biological plausibility and the low rate of missing data.


Eligibility criteria:
inclusion criteria: * all patients over 18 who undergoing hrs or krs with or without an eras intensified recovery program with any level of protocol compliance (0-100%) surgeries planned by inclusion criteria * total elective knee replacement surgery(primary) * total elective hip replacement surgery (primary) exclusion criteria: * patients undergoing emergency surgery. * partial prostheses * replacement of prosthesis * patients who decline to participate

Keywords: postoperative complications
topiramate augmentation in the treatment of obsessive-compulsive disorder

Conditions: Obsessive-compulsive Disorder

Summary: a 12-week program to examine the effectiveness of topiramate in adjunctive treatment for adults with obsessive-compulsive disorder and who are currently on serotonin reuptake inhibitor medications (ages 18-65).

the compulsive, impulsive and anxiety disorders program at the mount sinai school of medicine is conducting a study of topiramate (topamax) added to an ssri for the management of treatment-resistant obsessive-compulsive disorder. the purpose of the study is to evaluate the safety and efficacy of topiramate versus placebo added to a selective serotonin reuptake inhibitor (sri) in patients with treatment resistant ocd. the program is 12 weeks in duration and involves regular visits with a psychiatrist as well as complete psychiatric and medical evaluations. treatment and medication for the study will be provided free of charge.participants must be between the ages of 18 and 65 and have an onset of ocd at least 1 year prior to screening. in addition, participants must be taking a clinically effective dose of an ssri for at least 3 months and must maintain their current dose throughout the study. participants must not have a primary ocd symptom of hoarding.

Eligibility criteria:
inclusion criteria: males and females 18-65 years of age diagnosed with ocd and currently taking ssri medication(s) exclusion criteria: major medical disorders

Keywords: ocd obsessive-compulsive disorder ocd treatment
peripheral venous stent system in the treatment of iliac vein stenosis or occlusion

Conditions: Iliac Vein Stenosis; Iliac Vein Occlusion

Summary: clinical study on safety and efficacy of zylox peripheral venous stent system in the treatment of iliac vein stenosis or occlusion.

the purpose of this study was to evaluate the safety and efficacy of zylox peripheral venous stent system in the treatment of iliac vein stenosis or occlusive lesions compare with conventional venous stent.

Eligibility criteria:
inclusion criteria: * aged from 18 to 75 years old, male or female * subject's target lesions were stenosis and/or occlusion * ceap≥c3 * subjects were able to understand the purpose of the study, demonstrate full compliance with the program and sign informed consent exclusion criteria: * pregnant woman or who's pregnancy test is positive * lactation period woman or woman/man with fertility plan

Keywords: peripheral venous stent system iliac vein patency rate
glaucoma laser trial (glt) glaucoma laser trial followup study (gltfs)

Conditions: Open-Angle Glaucoma

Summary: to compare the safety and long-term efficacy of argon laser treatment of the trabecular meshwork with standard medical treatment for primary open-angle glaucoma.

during the last decade, argon laser trabeculoplasty (alt) has often been used instead of surgery as the treatment of choice in cases of open-angle glaucoma that could not be controlled by drugs. alt treatment consists of tiny laser burns evenly spaced around the trabecular meshwork. it sometimes has been found to be effective in controlling glaucoma, although many eyes still require some medical treatment. the glaucoma laser trial (glt), a randomized, controlled clinical trial, was conducted to determine whether alt is effective in patients with newly diagnosed, primary, open-angle glaucoma. each of the 271 patients in the trial received argon laser treatment in one eye and standard topical medication in the other eye. the eye to be started on medicine and the eye that would get the laser treatment were randomly selected. the glaucoma laser trial followup study was a followup study of 203 of the 271 patients who enrolled in the glaucoma laser trial. by the close of the glaucoma laser trial followup study, median duration of followup since diagnosis of primary, open-angle glaucoma was 7 years (maximum, 9 years). the argon laser treatment was done in two sessions 1 month apart, with one-half of the trabecular meshwork treated with 45 to 55 laser burns in each session. patients were seen for a followup visit 3 months after the first laser treatment and every 3 months thereafter for a period of at least 2 years. at each visit, examination of the eyes included a check of intraocular pressure and visual acuity. visual field examinations were performed 3, 6, and 12 months after randomization and annually thereafter. disc stereo photographs were taken 6 and 12 months after randomization and annually thereafter. the results of these examinations determined whether treatment should be changed. if the pressure in either eye had not been reduced to the desired level, the physician changed the medication in the eye treated with drops or started the use of drops in the laser-treated eye according to a standardized procedure being used in the trial. if intraocular pressure was still not successfully reduced, surgery or further laser treatment may have been required.

Eligibility criteria:
at the time of recruitment, patients had to be at least 35 years old with an intraocular pressure of at least 22 mm hg or greater in each eye and evidence of optic nerve damage in at least one eye.
the kanyakla study: a microclinic social network intervention for promoting engagement and retention in hiv care

Conditions: HIV

Summary: the purpose of this randomized controlled trial is to compare a social network-based behavioral intervention known as microclinics to standard hiv clinical care alone in helping patients receiving hiv care on mfangano, remba and ringiti islands, kenya remain adherent to clinic appointments. the study is designed to evaluate the effectiveness of microclinics on reducing gaps in clinical care, hiv viral load and hiv-related stigma, compared to standard hiv clinical care alone. by doing this research study, the investigators hope to learn whether microclinics are a useful social strategy for improving delivery of hiv treatment in rural kenya.


Eligibility criteria:
inclusion criteria: * must be currently receiving combination antiretroviral therapy (cart) or co-trimoxozole prophylaxis from one of the eligible study clinics: * is currently in care at study baseline, defined as having ≥1 medical care visit to receive medications (cart or prophylaxis) during the six months preceeding initiation of study enrollment, or * initiates pre-art or art care for the first time at a study clinic during the six month study recruitment period, or * transfers from a clinic outside the study area and receives pre-art or art care for the first time from a study clinic during the six month recruitment period * participants become eligible for study inclusion on the 4th day following a missed clinic appointment, provided the patient has not transferred care to another clinic prior to the 4th day, moved outside the study area or died. participants who miss a study visit by \>3 days but return to clinic before recruitment takes place are still eligible for study enrollment. missed visits must have occurred within the previous 90 days at the time of eligibility assessment to meet this inclusion criteria. * must currently reside on mfangano, remba or ringiti island. * must be conversant with one of the commonly spoken languages within the study area (i.e. dholuo, swahili or english; prior experience indicates that this represents \>99% of the adult population). * must be ≥18 years of age as of the date of study eligibility. exclusion criteria: * eligible participants who reside in the mfangano east sub-location will be excluded from participation in this study. many of these patients have already participated in the microclinic intervention as part of the mfangano island healthy network impact study. * participants planning on moving permanently out of the study area within the next six months will be excluded. * participants who, should they be randomized to the intervention arm, would be unwilling to participate in a microclinic will be excluded from study enrollment.

Keywords: hiv social network social support disclosure stigma kenya
evaluating the safety and efficacy of tradipitant vs. placebo in idiopathic and diabetic gastroparesis

Conditions: Idiopathic Gastroparesis; Diabetic Gastroparesis; Gastroparesis

Summary: to investigate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms of gastroparesis.


Eligibility criteria:
inclusion criteria: * diagnosed with gastroparesis * demonstrated delayed gastric emptying * presence of moderate to severe nausea * body mass index (bmi) of ≥18 and ≤40 kg/m2 exclusion criteria: * another active disorder or treatment which could explain or contribute to symptoms of gastroparesis * a positive test for drugs of abuse at the screening or evaluation visits; * exposure to any investigational medication in the past 60 days * gastrectomy, fundoplication, vagotomy, pyloroplasty, bariatric surgery, or gastric stimulation device surgically implanted within the last year

Keywords: gastroparesis idiopathic diabetic tradipitant nausea vomiting stomach motility functional nk-1 antagonist neurokinin 1 receptor substance p
tachykinin and kisspeptin expression in human granulosa and cumulus cells

Conditions: Infertility

Summary: the purpose of this project is to study the presence of expression differences - at rna and protein level - of different members of the tachykinin family and kisspeptin and their receptors, between fertile women and infertile patients with different etiologies.


Eligibility criteria:
two groups of subjects (each one with different criteria): 1. oocyte donors inclusion criteria: * age between 18 and 34 years * normal caryotype * normal psychological test exclusion criteria: * presence of hereditary diseases * beta-thalassemia * cystic fibrosis * human immunodeficiency virus (hiv), hepatitis b virus (hbv), hepatitis c virus (hcv) 2. infertility patients inclusion criteria: * age between 18 and 45 years * one of the following etiologies: * patient with pcos according to rotterdam criteria or * patients with endometriosis stage i-iv or * patients with low ovarian response according to bologna criteria or * patients with advances maternal age (between 38 and 45 years)

Keywords: infertility tachykinin kisspeptin
drug sensitivity detection of micro tumor (ptc) to guide postoperative adjuvant treatment strategy of colorectal cancer

Conditions: Colon Cancer; Rectal Cancer; Chemotherapy Effect; PTC; Exon Mutation

Summary: the research objectives is to compare vitro 3d drug sensitivity test results of micro tumor (ptc) with the clinical outcomes of patients, evaluate the consistency between the test results of the technology platform and the clinical prognosis, and explore the decision-making value and guiding significance of this technology in assisting the precise treatment of colorectal cancer. the completion of this study will provide real-world data support for the clinical application of micro tumor (ptc) in vitro 3d drug sensitivity detection technology, and provide more valuable reference basis for realizing the individualization and accuracy of colorectal cancer treatment and improving the clinical benefit rate.

the study is a multi agency prospective cohort study in china. the subjects were patients aged 18 \~ 75 years with colorectal cancer diagnosed by histopathology or cytology. they must be colorectal cancer patients who have at least one assessable tumor focus, need adjuvant therapy after radical surgery, and have not received neoadjuvant therapy， ecog physical condition score ≤ 2 points. and they must be voluntarily participate in and sign informed consent. the patients were randomly divided into ptc drug sensitivity test group and control group. the ptc drug sensitivity test group selected the adjuvant chemotherapy scheme according to the 3d drug sensitivity test results of micro tumor (ptc) in vitro. the control group made adjuvant chemotherapy strategy according to clinical experience. all exon (wes) data collection was used to predict postoperative survival in both groups. the primary endpoint was the non inferiority test, and the 3-year disease-free survival rate was t-c \>- δ

Eligibility criteria:
inclusion criteria: * age 18 \~ 75 years old, regardless of gender * patients with colorectal cancer diagnosed by histopathology or cytology * colorectal cancer patients who need adjuvant therapy after radical surgery and have not received neoadjuvant therapy * having at least one assessable tumor focus * ecog physical condition score ≤ 2 points * voluntarily participate and sign informed consent exclusion criteria: * patients diagnosed with metastasis * patients who cannot obtain tumor samples * pregnant and lactating women * patients with poor compliance * patients with severe cardiovascular and cerebrovascular complications who cannot receive adjuvant treatment * patients with other malignant tumors * suffering from serious mental and nervous system diseases * the researchers believe that patients should not be selected for this study
a clinical trial investigating the safety and efficacy of subjects with alcohol associated hepatitis (part 1)

Conditions: Alcohol Hepatitis

Summary: a phase 2 clinical trial investigating the safety and efficacy of adx-629 in subjects with moderate alcohol associated hepatitis (part 1)


Eligibility criteria:
inclusion criteria: * adult ≥ 21 years old on the day of signing the informed consent form; * clinical diagnosis of alcoholic hepatitis, based on clinical features and laboratory testing, confirmed by the investigator at screening * agreement to abstain from alcohol and utilize resources to cease at-risk behaviors during the trial, including addiction/alcohol abuse treatment * ability and willingness to swallow tablets * willingness to provide signed informed consent, prior to any trial-related procedures and willingness to comply with the trial procedures and requirements exclusion criteria: * pregnant, intending to become pregnant (or father a child), or breastfeeding * current or recent enrollment in another interventional trial in the 30 days prior to screening

Keywords: adx-629
retrospective ct imaging of biocomposite interference screw with btb

Conditions: ACL Tear

Summary: the purpose of this study is to examine the long-term appearance and resorption rate of biocomposite screws used during acl reconstruction on x-ray and computed tomography (ct).


Eligibility criteria:
inclusion criteria: * ages 18-50 * patients who underwent primary acl reconstruction performed by one of the study investigators at least 5 years ago * isolated acl tear * type of graft used was bone-patellar tendon-bone autograft * type of screw used to attach graft to the tibia and/or femur was a biocomposite interference screws (arthrex, inc.) * no degenerative joint disease on preoperative x-rays (\> 50% joint space loss, presence of osteophytes) exclusion criteria: * revision acl reconstructions * types of grafts other than bone-patellar tendon-bone autograft were used * acl tear with concomitant pathology * degenerative joint disease on preoperative x-ray (\> 50% joint space loss, presence of osteophytes) * metal or other types of bioabsorbable screws other than biocomposite interference screws (arthrex, inc.) were used * acl reconstruction performed less than 5 years ago * pregnancy * greater than grade 2 laxity of other ligaments * no additional fixation
evaluation of the subjective and objective painful threshold in multiple system atrophy pain and multiple system atrophy

Conditions: Pain Threshold; Multiple System Atrophy

Summary: multiple system atrophy (msa) is a sporadic neurodegenerative disorder. msa is dominated by autonomic/urogenital failure which may be associated with either parkinsonism (msa-p subtype) or with cerebellar ataxia (msa-c subtype). the prognostic of this disease is bad because it ended with the patient's death few years later. no neuroprotective treatment has shown a real efficacy. 50% of patients suffering of msa frequently experienced painful sensation. the origin of this pain is unknown. in parkinson disease (pd) ; arguments suggest the implication of dopamine neuromediator pathway in integration and modulation of pain. several studies suggest the existence of various influences with dopamine implication in the appearance of painful sensation and that would be inhibitory. that's why observed painful symptoms in msa and pd could be due to a decrease of pain appearance threshold, secondary to a lost of control of sensitizes centres, to parkinson control. it is interesting to determine if msa as pd is responsible for a decrease of pain threshold and to characterise the levodopa effect on the patient's pain threshold. better physiopathology knowledge of pain in msa is necessary to improve the therapeutic care. because the efficacy of others treatments is low, it's important to improve the research for a better comfort of patients with a better understanding, analysing and treating of the pain.


Eligibility criteria:
inclusion criteria: * patients from 50 to 80 years old (male and female) * patients suffering of a diagnosis possible or probable msa-p with the international criteria (2008). * patients with clinical diagnosis of parkinson's disease according to the criteria of the ukpdsbb (gibb et lees, 1988; hughes et al, 1992) * patients with no cognitive troubles * patients who give their informed and signed consent. * patients affiliated to a social protection program exclusion criteria: * patient suffering from an other parkinson syndrome than msa and pd, by example progressive supranuclear palsy, corticobasal degeneration... * patient suffering of a diagnosis possible or probable msa-c with the international criteria * patient suffering from another pathology causing chronic pain (rheumatic disease, traumatic or orthopedic pathologies...) * patient under tutelage, curatella or law protection

Keywords: subjective pain multiple system atrophy
predictive proteomic factors of the response to concomitant radiochemotherapy in esophageal cancer

Conditions: Esophageal Cancer

Summary: the scope of the trial is to predict the early complete clinical response to exclusive concomitant radiochemotherapy in esophageal cancer by the study of the pre- and per- therapeutic proteomic profile.

further informations will be provided by centre oscar lambret.

Eligibility criteria:
inclusion criteria: * invasive esophageal carcinoma at any stage (all t, n0 or n1, m0 or m1a), histologically proven * treated by exclusive concomitant radiochemotherapy * written informed consent exclusion criteria: * presence of a second uncontrolled cancer * metastatic carcinoma * metastatic disease, except cervical lymphnodes... (m1a) * in situ carcinoma * eso-gastric junction cancer (siewert ii ou iii) * inclusion in a clinical trial with an experimental drug during the study and until 15 weeks after the end of radiotherapy)

Keywords: oesophageal cancer exclusive concomitant radiochemotherapy